First case of PML in Tysabri-naive Gilenya patient
This article was originally published in Scrip
A multiple sclerosis patient taking Novartis's Gilenya (fingolimod) has been reported to have developed the potentially fatal condition PML (progressive multifocal leukoencephalopathy). Although rare cases of PML have been reported with Gilenya before, this is the first time such a case has not been associated with prior use of rival treatment, Tysabri (natalizumab; Biogen Idec; scripintelligence.com, 16 April 2012).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.